STOCK TITAN
  1. Home
  2. Sec-filings
  3. TARA
  4. [Form 4] Protara Therapeutics, Inc. Insider Trading Activity

Director at Protara Therapeutics (NASDAQ: TARA) awarded 31,000 stock options at $3.94

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Protara Therapeutics director Barry P. Flannelly received a grant of stock options covering 31,000 shares of common stock. The options have an exercise price of $3.94 per share and expire on June 14, 2036.

According to the grant terms, the 31,000 options vest in full on the first anniversary of the June 15, 2026 grant date, as long as the director continues serving on the board, and they vest in full upon a Change of Control.

Positive

  • None.

Negative

  • None.
Insider Flannelly Barry P
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 31,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 31,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 31,000 options Stock Option (Right to Buy) grant to director
Exercise price $3.94 per share Conversion/exercise price of stock options
Expiration date June 14, 2036 Option term end date
Underlying shares 31,000 shares Common stock underlying the options
Shares after transaction 31,000 options Total derivative holdings following grant
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Change of Control financial
"will vest in full upon a Change of Control"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
Annual Grant financial
"The shares subject to the Annual Grant will vest in full"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Flannelly Barry P
(Last)(First)(Middle)
C/O PROTARA THERAPEUTICS, INC.
345 PARK AVENUE SOUTH, 3RD FLOOR
(Street)
NEW YORK NEW YORK 10010
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$3.9406/15/2026A31,00006/15/2027(1)06/14/2036Common Stock31,000$031,000D
Explanation of Responses:
1. 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
Remarks:
/s/ Mary Grendell, Attorney-in-fact06/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What transaction did Protara Therapeutics (TARA) report in this Form 4?

Protara Therapeutics reported a director stock option grant for 31,000 shares. The options give the holder the right to buy common stock at a fixed $3.94 exercise price, expiring June 14, 2036, subject to the vesting conditions described.

Who is the insider in the Protara Therapeutics (TARA) Form 4 filing?

The insider is Barry P. Flannelly, a director of Protara Therapeutics. He received a stock option grant for 31,000 underlying common shares, with vesting tied to one year of continued board service or earlier upon a Change of Control event.

How many Protara Therapeutics (TARA) options were granted and at what price?

The filing shows a grant of stock options covering 31,000 shares of Protara Therapeutics common stock. These options carry an exercise price of $3.94 per share, meaning the director can buy shares at that price once the options vest.

When do the Protara Therapeutics (TARA) director options vest?

The 31,000 stock options vest in full on the first anniversary of the grant date. Vesting requires the director’s continuous service on the board through that date, and the options also vest in full upon a Change of Control of Protara Therapeutics.

What is the expiration date of the Protara Therapeutics (TARA) stock options?

The reported stock options expire on June 14, 2036. After this expiration date, any unexercised options become worthless, so the director must exercise vested options before that time to purchase Protara Therapeutics common shares at $3.94.

Is this Protara Therapeutics (TARA) Form 4 a market purchase or sale?

This Form 4 reflects a grant or award of stock options, not a market trade. The director acquired derivative rights to buy 31,000 shares at a $3.94 exercise price; no open-market buying or selling of common stock is reported here.